Edition:
United States

DexCom Inc (DXCM.OQ)

DXCM.OQ on NASDAQ Stock Exchange Global Select Market

54.01USD
17 Nov 2017
Change (% chg)

$0.99 (+1.87%)
Prev Close
$53.02
Open
$52.96
Day's High
$54.09
Day's Low
$52.21
Volume
567,187
Avg. Vol
495,402
52-wk High
$88.80
52-wk Low
$42.63

Chart for

About

Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company's products consist of DexCom G4 PLATINUM and DexCom G5 Mobile. The... (more)

Overall

Beta: 0.15
Market Cap(Mil.): $4,693.64
Shares Outstanding(Mil.): 86.90
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 51.22 15.79
EPS (TTM): -- -- --
ROI: -- 13.48 12.01
ROE: -- 20.00 15.91

BRIEF-Dexcom Inc reports Q3 GAAP loss per share $0.02

* Dexcom, inc. Reports record third quarter 2017 financial results

Nov 01 2017

BRIEF-‍Tandem Diabetes Care to provide all t:slim X2 insulin pump features approved in 2018 to users at no cost

* ‍Tandem Diabetes Care to provide all t:slim x2 insulin pump features approved in 2018 to users at no cost, expands existing dexcom welcome offer for animas customers​

Oct 24 2017

BRIEF-‍Janus Henderson reports 10.2 pct passive stake in Dexcom

* ‍Janus Henderson Group PLC reports a 10.2 percent passive stake in Dexcom Inc as of sept 30 - SEC filing​ Source text: (http://bit.ly/2ybb4kH) Further company coverage:

Oct 11 2017

BRIEF-Fitbit and Dexcom to develop Continuous Glucose Monitoring Experience for people living with diabetes

* ‍Fitbit and DexCom to develop Continuous Glucose Monitoring (CGM) experience for people living with diabetes​

Sep 07 2017

BRIEF-Tandem Diabetes Care announces FDA approval, launch of t:slim X2 insulin pump with Dexcom G5 mobile CGM integration

* Tandem Diabetes care announces FDA approval and launch of t:slim X2 insulin pump with Dexcom G5 mobile CGM integration

Aug 28 2017

BRIEF-DexCom ‍publishes new study on people with type 2 diabetes

* DexCom-‍ published new study showing type 2 diabetes people on a multiple daily injection insulin therapy benefit from use of continuous glucose monitoring​ Source text for Eikon: Further company coverage:

Aug 21 2017

BRIEF-Dexcom Q2 revenue $170.6 mln; names new CFO

* Q2 revenue $170.6 million versus I/B/E/S view $166.3 million

Aug 01 2017

BRIEF-Dexcom announces FDA approval of G5 mobile app for android devices

* Dexcom announces fda approval of g5 mobile app for android devices

Jun 07 2017

Competitors

  Price Chg
Roche Holding Ltd. (ROG.S) CHF230.10 +1.10
Roche Holding Ltd. (RO.S) CHF233.30 +1.30
Johnson & Johnson (JNJ.N) $138.00 -0.87
Abbott Laboratories (ABT.N) $55.56 +0.02
Medtronic PLC (MDT.N) $79.49 +0.23

Earnings vs. Estimates